ITEMS IN AFP WITH KEYWORD:
Case Study: A 61-year-old black man presents for a routine checkup. He has hypertension and diabetes mellitus that are well controlled with medication. During the visit, he tells you that a friend advised him to get a prostate-specific antigen (PSA) test to screen for prostate cancer, and he would like to pursue testing.
In the United States, more than 90 percent of prostate cancers are detected by serum prostate-specific antigen testing. Most patients are found to have localized prostate cancer, and most of these patients undergo surgery or radiotherapy. However, many patients have low-risk cancer and can follow an...
Apr 1, 2011 Issue
Screening for Prostate Cancer: Prostate-Specific Antigen Testing Is Not Effective [Cochrane for Clinicians]
Several large randomized controlled trials show that PSA screening does not significantly reduce prostate cancer mortality, even in a U.S. study that included black men and men with a family history of prostate cancer. However, PSA screening does lead to overdiagnosis, overtreatment, and treatment-associated morbidity.
Although there have been substantive advances in the understanding of prostate cancer screening since the previous American Cancer Society (ACS) guideline update in 2001, there are still uncertainties about the overall value of early detection. Evidence that periodic prostate-specific antigen (PSA) ...
The American Society of Clinical Oncology (ASCO) and American Urological Association (AUA) developed a practice guideline on the benefits and harms of 5-alpha reductase inhibitors for prevention of prostate cancer.
Aug 15, 2009 Issue
Screening for Prostate Cancer: Recommendation Statement [U.S. Preventive Services Task Force]
The U.S. Preventive Services Task Force (USPSTF) concludes that the current evidence is insufficient to assess the balance of benefits and harms of prostate cancer screening in men younger than 75 years.
Prostate cancer is the second most common cancer in men, with a lifetime prevalence of 17 percent. Prostate cancer symptoms generally occur in advanced stages, making early detection desirable. Digital rectal examination and prostate-specific antigen testing are the most commonly used screening tool...
There is insufficient evidence to determine whether screening for prostate cancer reduces mortality or impacts quality of life.
Dec 15, 2005 Issue
Predicting the Risk of Recurrence After Surgery for Prostate Cancer [Point-of-Care Guides]
A previous Point-of-Care Guide identified a clinical decision rule that estimates the likelihood of an abnormal biopsy for prostate cancer. One of the next questions facing the patient and his physician is the likelihood of recurrence after surgery.
Considerable uncertainty surrounds the screening, diagnosis, and management of prostate cancer.